Antenatal cystic fibrosis carrier screening—whether, when and how?

Zofia Miedzybrodzka*, Neva Haites, Marion Hall, Allan Templeton, Theresa Marteau, John Dean, Kevin Kelly, Ian Russell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Summary. Population screening for carriers of cystic fibrosis (CF) is now possible. Such screening may have both advantages and disadvantages and hence must be evaluated before it becomes routine practice. As the potential benefits of screening are wide and the drawbacks may include psychological effects, a combination of approaches is needed to assess screening thoroughly instead of only counting numbers of terminations or carrier tests. We describe the issues concerned and our methodology for a rigorous evaluation of population antenatal carrier screening for cystic fibrosis.

Original languageEnglish
Pages (from-to)368-375
Number of pages8
JournalPaediatric and Perinatal Epidemiology
Issue number4
Publication statusPublished - 1 Jan 1993


Dive into the research topics of 'Antenatal cystic fibrosis carrier screening—whether, when and how?'. Together they form a unique fingerprint.

Cite this